Pharsight

1. List of Briviact drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6911461	UCB INC	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	Feb, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653	UCB INC	Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives	Apr, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Aug 27, 2024

Drugs and Companies using BRIVARACETAM ingredient

Market Authorisation Date: 12 May, 2016

Treatment: Treatment of partial-onset seizures as adjunctive therapy in patients with epilepsy aged 16 years and older with epilepsy; Treatment of partial onset seizures in patients with epilepsy aged 16 years and older with epilepsy

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg/5 mL	12 May, 2020	2		21 Feb, 2026
10 mg/mL	12 May, 2020	1		21 Feb, 2026
10 mg, 25 mg, 50 mg, 75 mg and 100 mg	12 May, 2020	7	09 Jun, 2022	21 Feb, 2026	Eligible

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
25MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
75MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

2. List of Keppra drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802142	UCB INC	Pharmaceutical compositions comprising levetiracetam and process for their preparation	Jun, 2031 (8 years from now)
US8802142 (Pediatric)	UCB INC	Pharmaceutical compositions comprising levetiracetam and process for their preparation	Dec, 2031 (8 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 30 November, 1999

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
250 mg, 500 mg and 750 mg
1000 mg	24 Jan, 2007	1	15 Jan, 2009	14 Jul, 2008

Strength	Dosage	Availability
1GM	TABLET;ORAL	Prescription
250MG	TABLET;ORAL	Prescription
500MG	TABLET;ORAL	Prescription
750MG	TABLET;ORAL	Prescription

3. List of Keppra Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858122	UCB INC	Extended release formulation of levetiracetam	Sep, 2028 (5 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 12 September, 2008

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
500 mg and 750 mg	07 Jan, 2011	3	12 Sep, 2011	17 Sep, 2028	Eligible
1000 mg	07 Jan, 2011	2		17 Sep, 2028	Extinguished

Strength	Dosage	Availability
500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
750MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

4. List of Nayzilam drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687495	UCB INC	Methods and systems for the delivery of a therapeutic agent	Jan, 2028 (4 years from now)
US9289432	UCB INC	Methods and compositions for the delivery of a therapeutic agent	Jan, 2028 (4 years from now)
US8217033	UCB INC	Methods and compositions for the delivery of a therapeutic agent	Jan, 2028 (4 years from now)
US8809322	UCB INC	Methods and compositions for the delivery of a therapeutic agent	Jan, 2028 (4 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	May 21, 2022
Orphan Drug Exclusivity (ODE)	May 17, 2026

Drugs and Companies using MIDAZOLAM ingredient

Market Authorisation Date: 17 May, 2019

Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older

Dosage: SPRAY;NASAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg/spray	01 Jun, 2021	1		18 Jan, 2028

Strength	Dosage	Availability
5MG/SPRAY	SPRAY;NASAL	Prescription

5. List of Neupro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617591	UCB INC	Transdermal delivery system for the administration of rotigotine	Jul, 2023 (5 months from now)
US8246980	UCB INC	Transdermal delivery system	Nov, 2025 (2 years from now)
US8246979	UCB INC	Transdermal delivery system for the administration of rotigotine	Sep, 2027 (4 years from now)
US10130589	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Dec, 2030 (7 years from now)
US10350174	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Dec, 2030 (7 years from now)
US9925150	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Mar, 2032 (9 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Market Authorisation Date: 09 May, 2007

Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; Treatment of restless legs syndrome by application of claimed transdermal delivery system

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/24 hr 2 mg/24 hr 3 mg/24 hr 4 mg/24 hr 6 mg/24 hr 8 mg/24 hr	26 Nov, 2013	1		01 Sep, 2027

Strength	Dosage	Availability
1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
2MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
3MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
4MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
8MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

6. List of Vimpat drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE38551	UCB INC	Anticonvulsant enantiomeric amino acid derivatives	Mar, 2022 (10 months ago)

Exclusivity	Exclusivity Expiration
New Indication (I)	Nov 16, 2023
New Patient Population (NPP)	Oct 14, 2024

Drugs and Companies using LACOSAMIDE ingredient

Market Authorisation Date: 28 October, 2008

Treatment: Method of treating partial onset seizures in patients 4 years of age and older; Method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient with epilepsy aged 17 years or older; Method of use of treating, as an initial loading dose for monotherapy or adjunctive therapy in partial onset seizure patients with epilepsy aged 17 years or older; Method of use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older; Method of use for treatment of partial-onset seizures in patients 4 years of age and older

Dosage: SOLUTION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg/mL	29 Oct, 2012	3		17 Mar, 2022	Extinguished
50 mg, 100 mg, 150 mg, and 200 mg	29 Oct, 2012	14	17 Mar, 2022	17 Mar, 2022	Extinguished
10 mg/mL, 20 mL	30 Jun, 2016	1		17 Mar, 2022	Extinguished